On 22 March 2018, SHL Group will hold a live webinar to discuss how pharmaceutical companies can leverage a preconfigured device technology to bring their innovative drug formulations to market more efficiently.
The webinar, titled "The faster path to market: how pharma can benefit from using a robust and well-defined preconfigured drug delivery device," will be led by Dr Thomas P. Schönknecht, executive director of business development at SHL Group.
With the increase in chronic diseases and the emergence of biological and biosimilar drug formulations, self-injection devices have continued to see strong and consistent growth. More and more pharmaceutical companies are thereby leveraging preconfigured offerings to increase efficiency, reduce costs and ultimately shorten time-to-market for their novel therapies.
In the webinar, Dr Schönknecht will address this trend while exploring the challenges, opportunities and key traits of a successful preconfigured device. He will also look at the regulatory considerations that are required in order to support the approval as well as entire life-cycle of the drug product. Join Dr. Schönknecht to learn more about how to turn an innovative drug into a winning combination product.
Click here to register
Thomas P. Schönknecht, Ph.D., executive director, business development
Thomas Schönknecht is an executive director for business development at SHL Group. He has over 20 years’ experience in the pharmaceutical industry, working in various leading roles including project management, research and development, and business development for advanced drug delivery solutions.
Dr Schönknecht holds a Ph.D. in biophysical chemistry from the Max-Planck-Society and the University Goettingen, Germany and a master’s degree in chemistry from the University Goettingen. He is a frequent speaker, moderator and committee member at conferences regarding drug delivery and packing material science.